At the news
? NEUTRALIMPACT 3/10 8-K filed Jul 8, 2026 at 08:00 ET
Alkermes and Amneal Pharmaceuticals mutually terminated the Authorized Generic Product Supply Agreement for VIVITROL (naltrexone ER injectable suspension) after Amneal failed to meet certain terms and declined to order any batches. No penalties were incurred, and all claims were released. The agreement, which was contingent on a third-party ANDA product launch, had no revenue generated and no financial impact.
- Agreement terminated July 6, 2026, with Amneal not ordering any batches
- No penalties incurred by Alkermes; all claims released between parties
- Agreement was for a limited authorized generic version of VIVITROL, contingent on third-party ANDA launch
- No financial impact reported, no revenue was ever generated under the agreement
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access